Shanghai Henlius Biotech reported that China’s National Medical Products Administration (NMPA) accepted investigational new drug applications for three differentiated candidates targeting solid tumors. Acceptance triggers the transition from preclinical development to clinical testing in the Chinese regulatory system. Henlius framed the IND acceptances as a key step in its oncology expansion strategy, enabling first‑in‑human studies in China and potential global development depending on clinical results. The filings reflect continuing momentum in Chinese biopharma to advance locally developed tumor therapeutics into clinic.